Answers are grounded in this paper and cite their sources.
Observational analysis assesses the impact of pre-RAI scans in thyroid cancer treatment, indicating limited utility.
Context There is an evolving role for radioactive iodine (RAI) in thyroid cancer treatment. Radioactive iodine treatment usually involves a pre-RAI whole-body iodine scan and a posttherapy scan. The clinical utility of pre-RAI therapy scans has been increasingly questioned. Aim To evaluate the clinical utility of pre-RAI whole-body iodine scans. Methods We retrospectively reviewed the medical records of differentiated thyroid cancer patients treated with RAI. Using records blinded for pre-RAI scans, 3 endocrinologists developed empiric RAI treatment plans for each patient based on surgical pathology. This was repeated using the unblinded records, and the treatment plans made with and without pre-RAI scan results were compared. Results A total of 164 patients met the inclusion criteria: 89 patients (54.3%) were low risk, 61 (37.2%) intermediate risk, and 14 (8.5%) high risk for thyroid cancer recurrence. After blinded review, RAI treatment was recommended for 122 patients (74.3%); 46 were determined to be appropriate for a low-dose RAI, 75 a medium dose, and 1 a high dose. When unblinded, different recommendations were made for only 7 patients (5.7%), with 6 being recommended for a higher RAI dose. In addition, the prescan RAI results prompted recommendations for additional testing, such as neck ultrasounds or computed tomography or postoperative thyroglobulin levels. Pre-RAI scans affected patient care plans in only 7 (5.7%) of the 164 patients in the study. Conclusion In most patients with thyroid cancer who may need RAI, pre-RAI scans may not affect management, and empiric RAI doses may be a more cost-effective and convenient option.
No takes yet. Share an insight, caveat, or question.
Jaiswal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: